Watch IDXX. Know when insiders buy.
One email the day a filing lands. Free.
IDXX
IDEXX LABORATORIES INC /DE
553.48
−4.45 −0.80%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
29
FLAG · insiders 25, shorts 32
Insiders, 90 days
−$1.2M
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $43.6BP/E —DIV YIELD —FCF YIELD 2.88%REV TTM $4.6B +12.8%NET INCOME $1.1B +15.6%NET DEBT $253.1M52W 504.70 – 766.68SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.2B | +9.7% | 64.0% | $425.6M | $338.4M | +15.1% | — | $347.2M | $24.6M | $322.5M | Aug 4 |
| Q1 2026 · Mar 31 | $1.1B | +14.3% | 63.4% | $362.6M | $278.4M | +14.7% | — | $266.2M | $32M | $234.3M | Aug 4 |
| Q4 2025 · Dec 31derived | $1.1B | +14.3% | 60.3% | $315.6M | $248.2M | +14.8% | — | $355.8M | $29.4M | $326.3M | Feb 20 |
| Q3 2025 · Sep 30 | $1.1B | +13.3% | 61.8% | $354.8M | $274.6M | +17.9% | — | $402.3M | $31.1M | $371.2M | Nov 3 |
| Q2 2025 · Jun 30 | $1.1B | +10.6% | 62.6% | $373M | $294M | +44.6% | — | $185.7M | $34.1M | $151.6M | Aug 4 |
| Q1 2025 · Mar 31 | $998.4M | +3.6% | 62.4% | $316.5M | $242.7M | +3.0% | — | $238M | $30M | $207.9M | Aug 4 |
| Q4 2024 · Dec 31derived | $954.3M | +5.8% | 59.8% | $261.7M | $216.1M | +11.1% | — | $262M | $29.3M | $232.8M | Feb 20 |
| Q3 2024 · Sep 30 | $975.5M | +6.6% | 61.1% | $303.9M | $232.8M | +9.7% | — | $220.1M | $28.1M | $192M | Nov 3 |
| Q2 2024 · Jun 30 | $1B | — | 61.7% | $263.8M | $203.3M | — | — | $248.3M | $33.3M | $215M | Nov 3 |
| Q1 2024 · Mar 31 | $964.1M | — | 61.5% | $299M | $235.6M | — | — | $198.6M | $30.3M | $168.3M | Nov 3 |
| Q4 2023 · Dec 31derived | $901.6M | — | 58.4% | $245.3M | $194.5M | — | — | $249.9M | $32.6M | $217.3M | Feb 20 |
| Q3 2023 · Sep 30 | $915.5M | — | 59.9% | $275.3M | $212.2M | — | — | $272.4M | $34.1M | $238.3M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $4.3B | 61.8% | $1.4B | $1.1B | 24.6% | — | $1.2B | $124.7M | $1.1B | $1.2B | — |
| FY2024 · to Dec 31 | $3.9B | 61.0% | $1.1B | $887.9M | 22.8% | — | $929M | $120.9M | $808.1M | $837M | — |
| FY2023 · to Dec 31 | $3.7B | 59.8% | $1.1B | $845M | 23.1% | — | $906.5M | $133.6M | $772.9M | $71.9M | — |
| FY2022 · to Dec 31 | $3.4B | 59.5% | $898.8M | $679.1M | 20.2% | — | $543M | $148.8M | $394.1M | $819.7M | — |
| FY2021 · to Dec 31 | $3.2B | 58.8% | $932M | $744.8M | 23.2% | — | $755.5M | $119.5M | $636M | $746.8M | — |
| FY2020 · to Dec 31 | $2.7B | 58.0% | $694.5M | $581.8M | 21.5% | — | $648.1M | $107M | $541.1M | $182.8M | — |
Every number comes from IDEXX LABORATORIES INC /DE's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.